144 related articles for article (PubMed ID: 19090009)
1. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Bhatty M; Kato S; Piha-Paul SA; Naing A; Subbiah V; Huang HJ; Karp DD; Tsimberidou AM; Zinner RG; Hwu WJ; Javle M; Patel SP; Hu MI; Varadhachary GR; Conley AP; Ramzanali NM; Holley VR; Kurzrock R; Meric-Bernstam F; Kwang Chae Y; Kim KB; Falchook GS; Janku F
Cancer; 2019 Feb; 125(3):463-472. PubMed ID: 30383888
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Jamal R; Lapointe R; Cocolakis E; Thébault P; Kazemi S; Friedmann JE; Dionne J; Cailhier JF; Bélanger K; Ayoub JP; Le H; Lambert C; El-Hajjar J; van Kempen LC; Spatz A; Miller WH
J Immunother Cancer; 2017 Nov; 5(1):83. PubMed ID: 29157311
[TBL] [Abstract][Full Text] [Related]
4. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Algazi AP; Cha E; Ortiz-Urda SM; McCalmont T; Bastian BC; Hwang J; Pampaloni MH; Behr S; Chong K; Cortez B; Quiroz A; Coakley F; Liu S; Daud AI
Br J Cancer; 2015 Apr; 112(8):1326-31. PubMed ID: 25867272
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
[TBL] [Abstract][Full Text] [Related]
6. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
Guenterberg KD; Grignol VP; Relekar KV; Varker KA; Chen HX; Kendra KL; Olencki TE; Carson WE
Am J Clin Oncol; 2011 Feb; 34(1):87-91. PubMed ID: 20458209
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB; Cohen EI; Ocean A; Lehrer D; Goldenberg A; Knox JJ; Chen H; Clark-Garvey S; Weinberg A; Mandeli J; Christos P; Mazumdar M; Popa E; Brown RS; Rafii S; Schwartz JD
J Clin Oncol; 2008 Jun; 26(18):2992-8. PubMed ID: 18565886
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
Stopeck AT; Unger JM; Rimsza LM; Bellamy WT; Iannone M; Persky DO; Leblanc M; Fisher RI; Miller TP
Leuk Lymphoma; 2009 May; 50(5):728-35. PubMed ID: 19373598
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui N; Kamat N; Ravi V; Chawla S; Lohman M; Ganjoo KN
Rare Tumors; 2018; 10():2036361318771771. PubMed ID: 29760870
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A; Puzanov I; Dummer R; Schadendorf D; Hamid O; Robert C; Hodi FS; Schachter J; Pavlick AC; Lewis KD; Cranmer LD; Blank CU; O'Day SJ; Ascierto PA; Salama AK; Margolin KA; Loquai C; Eigentler TK; Gangadhar TC; Carlino MS; Agarwala SS; Moschos SJ; Sosman JA; Goldinger SM; Shapira-Frommer R; Gonzalez R; Kirkwood JM; Wolchok JD; Eggermont A; Li XN; Zhou W; Zernhelt AM; Lis J; Ebbinghaus S; Kang SP; Daud A
Lancet Oncol; 2015 Aug; 16(8):908-18. PubMed ID: 26115796
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.
Schuster C; Eikesdal HP; Puntervoll H; Geisler J; Geisler S; Heinrich D; Molven A; Lønning PE; Akslen LA; Straume O
PLoS One; 2012; 7(6):e38364. PubMed ID: 22719881
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Ott PA; Hamilton A; Min C; Safarzadeh-Amiri S; Goldberg L; Yoon J; Yee H; Buckley M; Christos PJ; Wright JJ; Polsky D; Osman I; Liebes L; Pavlick AC
PLoS One; 2010 Dec; 5(12):e15588. PubMed ID: 21206909
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
